Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus
by Sriparna Ghosal
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Roche, Thermo Fisher Scientific, Becton, Dickinson and Teladoc Health
Intel, Royal Caribbean Cruises, Roche, Thermo Fisher and Quest Diagnostics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intel, Royal Caribbean Cruises, Roche, Thermo Fisher and Quest Diagnostics highlighted as Zacks Bull and Bear of the Day
4 Potential Gainers Amid Intensifying Coronavirus Fears
by Trina Mukherjee
Amid the pandemonium associated with coronavirus, we look into four stocks that have the potential to benefit from this outbreak.
QIAGEN Gets CE Nod for QIAstat-Dx Respiratory SARS-CoV-2 Test
by Zacks Equity Research
The regulatory clearance of this test has made QIAGEN (QGEN) a key player in coronavirus diagnosis.
Coronavirus Testing Players Gain Momentum: 3 Stocks in Focus
by Sriparna Ghosal
There are several key diagnostic testing laboratory and biotech players whose prospects seem bright on account of rigorous work on developing diagnostic testing for the coronavirus.
Company News for Mar 18, 2020
by Zacks Equity Research
Companies In The News Are: PFE, BNTX, REGN, DNKN. TMO.
BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening
by Zacks Equity Research
BD (BDX) expects screening to ramp up by 1,000 per day once authorized.
Thermo Fisher (TMO) Gets EUA From FDA for COVID-19 Testing
by Zacks Equity Research
The emergency authorization of this test has made Thermo Fisher (TMO) a key player in the field of coronavirus diagnosis.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on the strong Q4 performance in the majority of its segments.
Thermo Fisher (TMO) to Buy Molecular Diagnostics Major QIAGEN
by Zacks Equity Research
Thermo Fisher (TMO) expects QIAGEN's strong molecular diagnostics presence to complement its specialty diagnostics capabilities.
Why Is Thermo Fisher (TMO) Down 9.1% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Why Western Digital (WDC) Might be Well Poised for a Surge
by Zacks Equity Research
Western Digital (WDC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Medical Product Stocks Likely to Beat This Earnings Season
by Trina Mukherjee
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Sonoco (SON) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Thermo Fisher (TMO) Q4 Earnings Top, Organic Growth Solid
by Zacks Equity Research
We are upbeat that two of Thermo Fisher's (TMO) four business segments deliver strong year-over-year revenue growth in Q4.
Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.28% and 0.67%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Thermo Fisher Scientific (TMO) Might Surprise This Earnings Season
by Zacks Equity Research
Thermo Fisher Scientific (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products' Jan 30 Earnings Roster: TMO, EW & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.